 Aeglea achieved primary endpoint in reducing arginine levels with its drug pegzilarginase for ARG1-D, which in turn reduced ammonia in the blood plasma, by an average of 80. BLA filing of pegzilarginase for patients with ARG1-D is expected to occur in 1st half of 2022. 